Riskpilot← Back to searchSign inGet full accessPharmaMénta Aps
APSActiveCVR 25615697Håndværkervej 32Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20002 employees
Revenue 2024
DKK 4,9M
+151% vs 2023
EBITDA margin
71.1%
+482% vs 2023
Equity ratio
13.9%
Financial strength
Net profit 2024
DKK 2,1M
+34293% vs 2023
| Revenue | DKK 4,9M | +151% |
| EBITDA | DKK 3,5M | +482% |
| Net profit | DKK 2,1M | +34293% |
| Total assets | DKK 20M | +6% |
| Equity | DKK 2,8M | +330% |
| Employees | 2 | — |
Legal name
PharmaMénta Aps
CVR number
25615697
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
15. september 2000
Share capital
DKK 200.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsen eller direktøren.
Company purpose
Selskabets formål er at drive handelsvirksomhed.
Address
Håndværkervej 32
Phone
+4576123375
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -6 | -7 | -2 | 126 | 1.343 | 1.120 | -5 | -246 | 1.733 | 2.656 | 1.720 | 1.940 | 4.868 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -927 | -1.187 | -997 | -1.120 | -1.198 | -1.266 |
| EBITDA | -6 | -7 | -2 | 126 | 1.343 | -4.880 | -5 | -1.173 | 547 | 1.660 | 484 | 594 | 3.460 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -68 | -115 | -176 | -205 | -234 |
| EBIT | -6 | -7 | -2 | 126 | 1.343 | -4.880 | -5 | -1.173 | 478 | 1.545 | 309 | 389 | 3.226 |
| Net financials | 232 | 190 | 166 | 135 | 133 | -11 | -3 | -14 | -83 | -175 | -273 | -368 | -490 |
| Profit before tax | 225 | 183 | 164 | 261 | 1.476 | -4.891 | -8 | -1.187 | 395 | 1.370 | 36 | 21 | 2.736 |
| Tax | -61 | 48 | 38 | 57 | 326 | 246 | -0 | -0 | -0 | 127 | 16 | 15 | 615 |
| Net profit | 286 | 136 | 125 | 204 | 1.150 | -5.138 | -8 | -1.187 | 395 | 1.242 | 20 | 6 | 2.121 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4.003 | 4.136 | 4.262 | 4.536 | 6.008 | 481 | 477 | 475 | 11.488 | 19.208 | 17.455 | 18.842 | 19.961 |
| Equity | 3.998 | 4.134 | 4.259 | 4.463 | 5.613 | 476 | 467 | -720 | -325 | 918 | 638 | 644 | 2.765 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 5 | 2 | 3 | 72 | 394 | 5 | 10 | 1.195 | 11.812 | 18.290 | 16.817 | 18.198 | 17.196 |
| Total debt | 5 | 2 | 3 | 72 | 394 | 5 | 10 | 1.195 | 11.812 | 18.290 | 16.817 | 18.198 | 17.196 |
EBITDA margin
71.1%
This company
15.8%
Market median
+350% vs market
20122024
Equity ratio
13.9%
This company
38.2%
Market median
-64% vs market
20122024
Return on equity
76.7%
This company
18.4%
Market median
+317% vs market
20122024
Net profit margin
43.6%
This company
8.1%
Market median
+438% vs market
20122024
Asset turnover
0.24×
This company
1.12×
Market median
-79% vs market
20122024
Debt / equity
6.22×
This company
0.62×
Market median
-903% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Management | Management | 2000 | — | — |
CE | Audit | 2000 | — | — |
SE Audit | Audit | 2001 | — | — |
JJ Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
NM Management | Management | 2007 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2004 | — | — | |
| Board of Directors | 2012 | — | — | |
| Chairman | 2012 | — | — | |
| Board of Directors | 2009 | — | — | |
| Board of Directors | 2004 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2001 | |
LHK Holding Esbjerg ApS | Company | 25.0% | 25.0% | 2019 |
JMINT Holding ApS | Company | 25.0% | 25.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PharmaMénta Aps also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Schierbeck | Management | 0 companies |
| Carl Edvard Gudbergsen | Audit | 0 companies |
| Svend Erik Jespersen | Audit | 0 companies |
| Jimmi Javed Christensen Malik | Chief Executive Officer | 0 companies |
| Nina Margrethe Egtved Knudsen | Management | 0 companies |
| Jørgen Makholm | Chairman | 0 companies |
| Tom Krongaard Thomsen | Board of Directors | 0 companies |
| Lasse Hvingelby Kikkenborg | Chairman | 0 companies |
| Janus Hvingelby Kikkenborg | Board of Directors | 0 companies |
| Max Terpager | Board of Directors | 0 companies |